Long Islanders suffering from sleep apnea inundated the sleep center at St. Charles Hospital in Port Jefferson with phone ...

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Health and Human Services Secretary Robert F. Kennedy Jr. and agency leaders have attributed a panoply of chronic diseases ...

A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results ...

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, ...

While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical ...

Ozempic-famed Novo Nordisk took over a $70 billion wipeout off its market value this week. Is this the beginning of a trend, ...

Several new weight loss drugs are undergoing trials in the UK. These drugs will work similarly to those already available but ...

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

We recently published 10 Stocks That Jim Cramer Talked About. CVS Health Corporation (NYSE:CVS) is one of the stocks Jim ...